BR112017021416A2 - anticorpos anti-flt-1 no tratamento de displasia broncopulmonar. - Google Patents
anticorpos anti-flt-1 no tratamento de displasia broncopulmonar.Info
- Publication number
- BR112017021416A2 BR112017021416A2 BR112017021416A BR112017021416A BR112017021416A2 BR 112017021416 A2 BR112017021416 A2 BR 112017021416A2 BR 112017021416 A BR112017021416 A BR 112017021416A BR 112017021416 A BR112017021416 A BR 112017021416A BR 112017021416 A2 BR112017021416 A2 BR 112017021416A2
- Authority
- BR
- Brazil
- Prior art keywords
- flt
- antibodies
- treatment
- bronchopulmonary dysplasia
- bronchopulmonary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144247P | 2015-04-07 | 2015-04-07 | |
| PCT/US2016/026436 WO2016164579A1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017021416A2 true BR112017021416A2 (pt) | 2018-07-03 |
Family
ID=55795198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017021416A BR112017021416A2 (pt) | 2015-04-07 | 2016-04-07 | anticorpos anti-flt-1 no tratamento de displasia broncopulmonar. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10711065B2 (pt) |
| EP (2) | EP3280735B1 (pt) |
| JP (2) | JP6797825B2 (pt) |
| CN (1) | CN107683143A (pt) |
| AU (2) | AU2016246738B2 (pt) |
| BR (1) | BR112017021416A2 (pt) |
| CA (1) | CA2981961A1 (pt) |
| HK (1) | HK1249913A1 (pt) |
| MA (1) | MA41900A (pt) |
| MX (1) | MX2017012831A (pt) |
| WO (1) | WO2016164579A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3094391A1 (en) * | 2018-03-22 | 2019-09-26 | The Children's Medical Center Corporation | Methods and compositions relating to lung repair |
| EP3810652A1 (en) * | 2018-06-22 | 2021-04-28 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| CA2922031C (en) * | 2002-07-19 | 2020-12-15 | Beth Israel Deaconess Medical Center, Inc. | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| JP4864900B2 (ja) | 2004-11-18 | 2012-02-01 | イムクローン・リミテッド・ライアビリティ・カンパニー | 血管内皮成長因子受容体−ｉに対する抗体 |
| US20060153835A1 (en) * | 2005-01-12 | 2006-07-13 | Smith Henry J | Treatment of pre-eclampsia in pregnant women using targeted apheresis |
| US8349325B2 (en) * | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
| WO2012109282A2 (en) * | 2011-02-07 | 2012-08-16 | Agamin Pharmaceuticals, Llc | Methods and systems for treating or preventing pregnancy-related hypertensive disorders |
| EP2948476B1 (en) | 2013-01-28 | 2018-06-06 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
| TW201517916A (zh) | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
-
2016
- 2016-04-07 EP EP16717527.2A patent/EP3280735B1/en active Active
- 2016-04-07 MX MX2017012831A patent/MX2017012831A/es unknown
- 2016-04-07 BR BR112017021416A patent/BR112017021416A2/pt active Search and Examination
- 2016-04-07 CA CA2981961A patent/CA2981961A1/en active Pending
- 2016-04-07 EP EP22156748.0A patent/EP4063390A1/en active Pending
- 2016-04-07 AU AU2016246738A patent/AU2016246738B2/en active Active
- 2016-04-07 JP JP2017552909A patent/JP6797825B2/ja active Active
- 2016-04-07 WO PCT/US2016/026436 patent/WO2016164579A1/en active Application Filing
- 2016-04-07 MA MA041900A patent/MA41900A/fr unknown
- 2016-04-07 US US15/565,009 patent/US10711065B2/en active Active
- 2016-04-07 CN CN201680032821.0A patent/CN107683143A/zh active Pending
-
2018
- 2018-07-19 HK HK18109380.9A patent/HK1249913A1/zh unknown
-
2020
- 2020-06-05 US US16/893,999 patent/US20210130475A1/en not_active Abandoned
- 2020-11-18 JP JP2020191516A patent/JP2021014473A/ja active Pending
-
2022
- 2022-03-15 AU AU2022201781A patent/AU2022201781A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016246738B2 (en) | 2021-12-16 |
| HK1249913A1 (zh) | 2018-11-16 |
| AU2016246738A8 (en) | 2017-12-21 |
| JP2021014473A (ja) | 2021-02-12 |
| EP3280735B1 (en) | 2022-02-16 |
| EP3280735A1 (en) | 2018-02-14 |
| EP4063390A1 (en) | 2022-09-28 |
| US20180100017A1 (en) | 2018-04-12 |
| US10711065B2 (en) | 2020-07-14 |
| MX2017012831A (es) | 2018-05-04 |
| US20210130475A1 (en) | 2021-05-06 |
| CN107683143A (zh) | 2018-02-09 |
| MA41900A (fr) | 2021-06-02 |
| AU2022201781A1 (en) | 2022-04-07 |
| JP6797825B2 (ja) | 2020-12-09 |
| CA2981961A1 (en) | 2016-10-13 |
| JP2018517667A (ja) | 2018-07-05 |
| AU2016246738A1 (en) | 2017-10-26 |
| WO2016164579A1 (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| DK3110843T3 (da) | Kombinationsterapier med anti-cd38-antistoffer | |
| BR112017017582A2 (pt) | sistema de tratamento oral | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| DK3113797T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| DK3265123T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| DK3099791T3 (da) | Protein | |
| DK3416974T3 (da) | Proteinoprensning | |
| DK3223869T3 (da) | Gelatineoprensning | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| DK3099793T3 (da) | Protein | |
| BR112016015712A8 (pt) | método de tratamento de doenças hepáticas. | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| HK1249908A1 (zh) | 治療支氣管肺發育不良的抗flt-1抗體 | |
| DK3102862T3 (da) | Udblæsningsventil med reduceret udstrømning | |
| BR112017021416A2 (pt) | anticorpos anti-flt-1 no tratamento de displasia broncopulmonar. | |
| KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 | |
| GB201500875D0 (en) | Antibodies for treatment and diagnosis | |
| ITUA20163619A1 (it) | Corpo radiante e metodo per la realizzazione dello stesso corpo radiante. | |
| FI20155649A (fi) | Jaettu runko | |
| FI11598U1 (fi) | Pilkekoneen runkorakenne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA FARMACEUTICAL COMPANY LIMITED (JP) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: SHIRE HUMAN GENETIC THERAPIES, INC. (US) Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2634 DE 29/06/2021 POR TER SIDO INDEVIDA. |
|
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |